Caralluma dalzielii
Caralluma dalzielii · Accepted scientific name
Scientific literature: Very Sparse (1 studies) · ★☆☆☆☆
Caralluma dalzielii is a remarkable medicinal plant recognized for its diverse range of therapeutic applications in traditional medicine. Research indicates that its aqueous extract possesses significant antinociceptive activities, making it valuable for pain management. This species has been historically utilized in the treatment of various complex conditions, including leprosy and fungal diseases. Furthermore, it shows potential in managing debilitating ailments such as rheumatoid arthritis and convulsions. Understanding its chemical properties provides insight into its profound pharmacological importance.
- Synonyms
- Ceropegia Sudanica · Caralluma Sudanica
- Common names
- Not available
- Family
- Apocynaceae
- Distribution
- Not available
- Plant Parts
- Not available
Classification
Synonyms
Caralluma dalzielii is a plant species that is often identified through various botanical synonyms. In many scientific records, it is formally recognized under the name Caralluma sudanica. Additionally, some taxonomic classifications list the plant as Ceropegia sudanica. These overlapping names can sometimes create confusion for researchers studying its specific characteristics. Understanding these relationships is essential for accurate identification within the complex landscape of plant taxonomy.
Sources: The World Checklist of Vascular Plants (WCVP)
Taxonomy
Caralluma dalzielii is a distinctive member of the kingdom Plantae. This species is classified under the class Equisetopsida and belongs to the order Gentianales. Within this biological framework, it is categorized under the family Apocynaceae. Furthermore, the plant is a specific representative of the genus Caralluma. Understanding these taxonomic relationships provides essential insight into its evolutionary place in the natural world.
| Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Phylum | Streptophyta |
| Class | Equisetopsida |
| Subclass | Magnoliidae |
| Order | Gentianales |
| Family | Apocynaceae |
| Genus | Caralluma |
Sources: The World Checklist of Vascular Plants (WCVP)
Distribution
Geographic Regions
Caralluma dalzielii is a plant species with a broad geographical footprint across the African continent. Its distribution spans from the regions of Northeast Tropical Africa, including Sudan and South Sudan, into the heart of West Tropical Africa. Within the western reaches, the species is notably documented in countries such as Benin, Burkina Faso, and Ghana. It also maintains a presence in the arid landscapes of Mali, showcasing its adaptability to various environments. This wide-ranging presence highlights the significant role the plant plays within diverse African ecosystems.
Sources: The World Checklist of Vascular Plants (WCVP)
Identification
Morphology
Caralluma dalzielii is characterized by its distinct growth form as an herb.
Sources: Global Inventory of Floras and Traits (GIFT)
Biological Activities
Caralluma dalzielii has long been utilized in traditional medicine across Northern Nigeria to treat various ailments, including pain and inflammatory conditions. Recent scientific investigations have sought to validate these traditional uses by evaluating the plant's pharmacological properties through animal models. The results demonstrated that the aqueous extract of the plant possesses significant antinociceptive activity, effectively reducing pain across several testing methods. These effects were found to be dose-dependent, with higher concentrations yielding a more substantial inhibition of nociception. Ultimately, these findings suggest that the antinociceptive properties of Caralluma dalzielii provide a scientific basis for its historical use in managing pain.
Compounds
Conditions
Caralluma dalzielii is traditionally utilized in Northern Nigeria for treating various ailments, including convulsion and fungal diseases. Scientific evaluations of its aqueous extract demonstrate strong antinociceptive activity, specifically as it treats the acetic acid induced writhing test in mice. The plant also shows significant efficacy in treating formalin induced oedema in rats. These results provide evidence for its ability to treat inflammatory diseases through dose-dependent mechanisms. Overall, the extract's performance across these models supports its medicinal use for pain and inflammation.
Preparations
Caralluma dalzielii is prepared as an aqueous extract to investigate its medicinal properties. This specific preparation was utilized to evaluate the plant's antinociceptive and anti-inflammatory effects in various animal models. Researchers applied three different doses of this aqueous extract, specifically 25, 50, and 100 mg/kg, during the assessment. The study found that the extract produced significant, dose-dependent inhibition of pain and swelling across multiple tests. Consequently, the efficacy of the aqueous extract supports the traditional use of the plant for treating inflammatory diseases and pain.